Tebapivat Development Halted Due to Failure to Demonstrate Clinical Differentiation

Agios Pharmaceuticals (AGIO) has announced the discontinuation of all clinical development programs for tebapivat (AG-946), its next-generation treatment candidate for sickle cell disease (SCD). This decision follows the failure of tebapivat, an oral pyruvate kinase (PK) activator, to demonstrate superior efficacy compared to existing treatments in the ongoing Phase 2 clinical trial. While tebapivat showed biological activity, including improvements in red blood cell metabolism and hemoglobin levels, it did not demonstrate sufficient clinical differentiation to secure a competitive advantage in the market, leading to the termination of the program. This follows the previous discontinuation of the low-risk myelodysplastic syndrome (LR-MDS) clinical trial in May 2026, effectively ending the tebapivat program.

Loss of Competitive Edge Against Novo Nordisk's Etavopivat

The discontinuation of tebapivat has resulted in a loss of competitive advantage against Novo Nordisk (NVO) in the next-generation SCD treatment market. Novo Nordisk acquired Forma Therapeutics in 2022 for $1.1 billion and subsequently announced positive results from the Phase 3 (HIBISCUS) trial of etavopivat, its PK activator. Etavopivat demonstrated a 27% reduction in vaso-occlusive crises (VOCs) and improved hemoglobin levels in 48.7% of patients, and is expected to be submitted for regulatory approval in the second half of 2026. With the loss of tebapivat, Agios no longer has a strong contender to compete with etavopivat in the market.

Harsh Realities of Developing New Drugs for Rare Blood Disorders

Recently, several companies that have attempted to develop SCD treatments in the global biopharma landscape have faced setbacks. Fulcrum Therapeutics (FULC) is considering selling the company due to safety concerns with pociredir, and Pfizer (PFE) withdrew Oxbryta from the market due to adverse event issues, despite having acquired it for $5.4 billion. Novartis (NVS) also experienced the revocation of the European approval for Adakveo, highlighting the significant barriers to entry in this market. These repeated failures underscore the challenges of overcoming the complexity of the target mechanism and meeting stringent safety requirements.

Focus on Mitapivat and Business Development

Agios will now focus all its resources and commercial efforts on mitapivat (Pyrukynd), its lead asset, which is administered twice daily. Mitapivat has been submitted to the FDA for additional new drug application (sNDA) approval based on the results of the global Phase 3 (RISE UP) trial, and has received Priority Review designation, with a PDUFA target action date of November 1, 2026. Market analysts believe that Agios needs to secure a successful regulatory approval for mitapivat to defend its stock price, which has fallen by approximately 6.5% to $37.50. In addition, the company is advised to actively pursue business development opportunities to acquire promising early-stage pipeline assets.